GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

Stay on top of your weight journey the smart way with CNET's top picks of the best smart scales, tested by our health experts. I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the ...

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

We were particularly pleased to see the momentum now being established in our oncology business, and I'm delighted that we filed Blenrep in Europe ... by building scale and momentum in our ...

The best kitchen scales are accurate and easy to use – a must-have for any gourmand or keen baker. Our expert testing goes further than other reviews, using calibrated weights from 1g to 1kg to find ...

Here’s how it works. The best smart scales help you keep tabs on more than just your weight. These scales have sensors to track your body composition, heart rate, and BMI, with the data easily ...

If elements are too small and text too hard to read, you probably need to adjust the scale settings. When you purchase through links on our site, we may earn an affiliate commission. Here’s how ...

Back in late 2022, GSK pulled the multiple myeloma ADC Blenrep from the U.S. market merely days after announcing a phase 3 trial flop. The British pharma is now aiming to reintroduce the drug in ...

Fish scales are essential when you catch a new personal best and want to remember it for the rest of your life. Good scales are accurate, easy to use, and have great battery life for when you need ...

Blenrep, a treatment for cancer, and asthma medicine Depemokimab are among the planned new launches. Nonetheless, shares in the company fell after it cut its outlook for its annual vaccines sales ...

Blenrep, a treatment for cancer, and asthma medicine Depemokimab are among the planned new launches. Nonetheless, shares in the company fell after it cut its outlook for its annual vaccines sales to a ...